UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 94

Sortiert nach

Systematic review and network meta‐analysis: first‐ and second‐line biologic therapies for moderate‐severe Crohn's disease

Alimentary pharmacology & therapeutics, 2018-08, Vol.48 (4), p.394-409

2018

Volltextzugriff (PDF)

Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update

Clinical pharmacology and therapeutics, 2013-04, Vol.93 (4), p.324-325

2013

Volltextzugriff (PDF)

Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing

Clinical pharmacology and therapeutics, 2011-03, Vol.89 (3), p.387-391

2011

Volltextzugriff (PDF)

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

Alimentary pharmacology & therapeutics, 2018-07, Vol.48 (1), p.65-77

2018

Volltextzugriff (PDF)

A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity

Alimentary pharmacology & therapeutics, 2015-01, Vol.41 (1), p.77-86

2015

Volltextzugriff (PDF)

Development of interim patient‐reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials

Alimentary pharmacology & therapeutics, 2015-11, Vol.42 (10), p.1200-1210

2015

Volltextzugriff (PDF)

The epidemiology and natural history of Crohn’s disease in population‐based patient cohorts from North America: a systematic review

Alimentary pharmacology & therapeutics, 2002-01, Vol.16 (1), p.51-60

2002

Volltextzugriff (PDF)

Long‐term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7‐year results from the PRECiSE 3 study

Alimentary pharmacology & therapeutics, 2014-10, Vol.40 (8), p.903-916

2014

Volltextzugriff (PDF)

Review article: biological activity markers in inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2007-02, Vol.25 (3), p.247-255

2007

Volltextzugriff (PDF)

Systematic review: the management of pouchitis

Alimentary pharmacology & therapeutics, 2006-04, Vol.23 (8), p.1087-1096

2006

Volltextzugriff (PDF)

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease

Alimentary pharmacology & therapeutics, 2010-06, Vol.31 (12), p.1296-1309

2010

Volltextzugriff (PDF)

Rational dosing of azathioprine and 6-mercaptopurine

Gut, 2001-05, Vol.48 (5), p.591-592

SANDBORN, W J

2001

Volltextzugriff (PDF)

Ulcerative colitis in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival

Gut, 2000-03, Vol.46 (3), p.336-343

2000

Volltextzugriff (PDF)

Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn’s disease

Alimentary pharmacology & therapeutics, 2010-08, Vol.32 (3), p.384-393

2010

Volltextzugriff (PDF)

Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide

Gut, 2001-11, Vol.49 (5), p.656-664

2001

Volltextzugriff (PDF)

Crohn's disease in Olmsted County, Minnesota, 1940–1993: Incidence, prevalence, and survival

Gastroenterology (New York, N.Y. 1943), 1998-06, Vol.114 (6), p.1161-1168

1998

Volltextzugriff (PDF)

Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort

Gastroenterology (New York, N.Y. 1943), 1999-07, Vol.117 (1), p.49-57

1999

Volltextzugriff (PDF)

MMX mesalazine for the induction of remission of mild‐to‐moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations

Alimentary pharmacology & therapeutics, 2008-06, Vol.27 (11), p.1094-1102

2008

Volltextzugriff (PDF)

Biologics in inflammatory bowel disease: how much progress have we made?

Gut, 2004-09, Vol.53 (9), p.1366-1373

2004

Volltextzugriff (PDF)

Repifermin (keratinocyte growth factor‐2) for the treatment of active ulcerative colitis: a randomized, double‐blind, placebo‐controlled, dose‐escalation trial

Alimentary pharmacology & therapeutics, 2003-06, Vol.17 (11), p.1355-1364

2003

Volltextzugriff (PDF)

Azathioprine: State of the Art in Inflammatory Bowel Disease

Scandinavian journal of gastroenterology, 1998, Vol.33 (234), p.92-99

Sandborn, W. J.

1998

Volltextzugriff (PDF)

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

The New England journal of medicine, 2005-12, Vol.353 (23), p.2462-2476

2005

Volltextzugriff (PDF)

The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota

Gut, 2007-04, Vol.56 (4), p.504-508

2007

Volltextzugriff (PDF)

Colonic motility in chronic ulcerative proctosigmoiditis and the effects of nicotine on colonic motility in patients and healthy subjects

Alimentary pharmacology & therapeutics, 2001-05, Vol.15 (5), p.653-663

2001

Volltextzugriff (PDF)

Pouchitis After Ileal Pouch-Anal Anastomosis: A Pouchitis Disease Activity Index

Mayo Clinic proceedings, 1994-05, Vol.69 (5), p.409-415

1994

Volltextzugriff (PDF)

1 – 25 von 94

Suche als RSS-Feed

Aktive Filter

SpracheJapanisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(90)
Mit Volltextzugriff
(79)

Publikationsform

Artikel
(93)
Reviews
(1)

Sprache

Englisch
(94)

Erscheinungsjahr

n.n

Thema

Science & Technology
(85)
Humans
(84)
Life Sciences & Biomedicine
(83)
Gastroenterology & Hepatology
(69)
Adult
(52)
Female
(52)
Male
(52)
Biological And Medical Sciences
(44)
Medical Sciences
(44)
Middle Aged
(39)
Aged
(28)
Gastroenterology. Liver. Pancreas. Abdomen
(27)
Other Diseases. Semiology
(26)
Stomach. Duodenum. Small Intestine. Colon. Rectum. Anus
(26)
Inflammatory Bowel Disease
(22)
Gastroenterology
(21)
Adolescent
(20)
Crohn Disease - Drug Therapy
(20)
Crohn's Disease
(19)
Pharmacology & Pharmacy
(19)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Systematic review and network meta‐analysis: first‐ and second‐line biologic therapies for moderate‐severe Crohn's disease

Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update

Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity

Development of interim patient‐reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials

The epidemiology and natural history of Crohn’s disease in population‐based patient cohorts from North America: a systematic review

Long‐term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7‐year results from the PRECiSE 3 study

Review article: biological activity markers in inflammatory bowel disease

Systematic review: the management of pouchitis

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease

Rational dosing of azathioprine and 6-mercaptopurine

Ulcerative colitis in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival

Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn’s disease

Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide

Crohn's disease in Olmsted County, Minnesota, 1940–1993: Incidence, prevalence, and survival

Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort

MMX mesalazine for the induction of remission of mild‐to‐moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations

Biologics in inflammatory bowel disease: how much progress have we made?

Repifermin (keratinocyte growth factor‐2) for the treatment of active ulcerative colitis: a randomized, double‐blind, placebo‐controlled, dose‐escalation trial

Azathioprine: State of the Art in Inflammatory Bowel Disease

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota

Colonic motility in chronic ulcerative proctosigmoiditis and the effects of nicotine on colonic motility in patients and healthy subjects

Pouchitis After Ileal Pouch-Anal Anastomosis: A Pouchitis Disease Activity Index

Aktive Filter

Suchergebnisse filtern